RECRUITING

Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Using a stepped-wedge randomized controlled trial, the study will test whether a clinic-level multidimensional intervention conducted in 36 opioid treatment programs (OTPs) will improve clinical decision making, regulatory confusion, legal liability concerns, capacity for clinical practice change, and financial barriers to take- home dosing (THD) for methadone as compared to treatment as usual.

Official Title

Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder: A Stepped-Wedge Randomized Trial to Facilitate Clinic Level Changes

Quick Facts

Study Start:2023-01-27
Study Completion:2027-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05675735

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Clinic staff inclusion will include anyone who works at the 10 clinics that the OASAS client data system generates from the quantitative analysis in year one. In years 2-5, clinics chosen by the OASAS client data system will be placed into six cohorts. Only staff from these clinics will be eligible.
  2. * Patient inclusion will include anyone aged 18 or older who has been receiving take-home methadone for at least 30 days.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Charles Neighbors, PhD
CONTACT
646-501-3875
Charles.Neighbors@nyulangone.org
Kamila Kiszko
CONTACT
646-501-3879
Kamila.Kiszko@nyulangone.org

Principal Investigator

Charles Neighbors, PhD
PRINCIPAL_INVESTIGATOR
NYU Langone Health

Study Locations (Sites)

University of Connecticut
Storrs, Connecticut, 06268
United States
University at Buffalo
Buffalo, New York, 14260
United States
NYU Langone Health
New York, New York, 10016
United States
Weill Cornell Medical College
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Charles Neighbors, PhD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-27
Study Completion Date2027-08-31

Study Record Updates

Study Start Date2023-01-27
Study Completion Date2027-08-31

Terms related to this study

Additional Relevant MeSH Terms

  • Problems Related to Social Environment